Nicotine Gum and Patches
Controlled Nicotine Delivery, Human Research, Cognition, Inflammation and Emerging Health Possibilities
Nicotine is a naturally occurring alkaloid produced by the tobacco plant. When nicotine is provided through gum or a transdermal patch, it becomes possible to deliver a measured amount and study its effects in a controlled way.
That simple change has opened an unexpectedly broad field of human research.
Nicotine gum and patches have been explored in studies involving attention, memory, mild cognitive impairment, neurological function, ulcerative colitis, inflammatory signaling, cardiovascular health, mood, Long COVID and post-infectious symptoms.
A systematic review identified 33 studies involving 987 nonsmokers or former smokers who received transdermal nicotine for longer than 48 hours. The research included randomized trials, crossover studies and additional clinical investigations across multiple conditions.
That history invites a larger question:
What can controlled nicotine teach us about the human body and the nicotinic receptor system it interacts with?
Focus of This Discussion
This page explores:
Nicotine as a naturally occurring tobacco alkaloid
Nicotine gum
Nicotine patches
Controlled nicotine delivery
Nicotinic acetylcholine receptors
Human research involving people without regular nicotine use
Attention, focus and cognition
Memory and mild cognitive impairment
Mood and late-life cognitive health
Neurological research
Ulcerative colitis and inflammatory signaling
Long COVID and post-infectious research
Cardiovascular research
Nicotine delivery and dependence
Dr. Bryan Ardis and the modern nicotine conversation
Practical differences between gum and patches
Possibilities still being explored in medicinal nicotine research
The focus is nicotine itself, measured gum and patch preparations, and the human and scientific research surrounding them.
Nicotine Connects With a System Already Within the Human Body
Nicotine interacts with nicotinic acetylcholine receptors, usually abbreviated nAChRs.
These receptors are naturally present throughout the human body. Their natural signaling molecule is acetylcholine, one of the body's major neurotransmitters.
Nicotinic receptors participate in processes involving:
Attention
Alertness
Learning
Memory
Movement
Sensory processing
Motivation
Autonomic function
Muscle activation
Digestion
Pain signaling
Immune communication
Inflammatory regulation
Different nicotinic receptor subtypes appear in different tissues and perform different functions.
This helps explain something that initially seems surprising: researchers interested in the brain, digestive tract, immune system and post-infectious illness can all find themselves studying the same nicotine-responsive receptor family.
Nicotine gives researchers a way to interact with this remarkable signaling system.
Why Controlled Delivery Changes the Story
Nicotine gum and nicotine patches contain nicotine, but they create distinctly different exposure patterns.
Nicotine gum provides shorter, adjustable exposure through absorption primarily across the lining of the mouth.
Nicotine patches provide gradual transdermal delivery across many hours.
That gives each preparation its own character.
Nicotine GumNicotine PatchOral absorptionTransdermal absorptionShorter exposureSustained exposureTiming can be individually controlledGradual delivery across many hoursUseful for intermittent exposureUseful for steady exposureCommonly available in measured strengthsAvailable in graduated strengths
This difference is important because nicotine's biological effects are influenced by how quickly it arrives, how much is delivered and how long receptors encounter it.
The molecule matters.
The delivery matters too.
Nicotine Gum
Nicotine gum contains nicotine bound to a resin known as nicotine polacrilex.
Rather than functioning like ordinary chewing gum, it is designed to allow nicotine to be absorbed through the tissues of the mouth.
Commercial gum is available in measured strengths, making intermittent nicotine exposure possible.
This creates an important practical difference from a patch:
Gum allows greater control over timing.
Researchers have used oral nicotine in studies of cognition, attention and neurological performance because a defined amount can be administered and its effects observed over a shorter period.
Nicotine Patches
A nicotine patch takes a different approach.
Nicotine gradually passes through the skin into systemic circulation, creating sustained exposure across many hours.
That makes the patch particularly interesting when researchers want prolonged nicotinic receptor engagement rather than a shorter exposure.
Human studies have explored transdermal nicotine in connection with:
Attention
Memory
Mild cognitive impairment
Age-related cognitive changes
Mood and cognition
Neurological conditions
Ulcerative colitis
Inflammatory signaling
Long COVID
Post-infectious symptoms
Cardiovascular response
The breadth of this research is one of the clearest indications that nicotine's biological story reaches far beyond one organ system.
Nearly 1,000 Nonsmokers in Transdermal Nicotine Research
One of the most valuable pieces of evidence for understanding controlled nicotine comes from a systematic review of transdermal nicotine in nonsmokers.
Researchers reviewed 35 publications representing 33 studies.
Together, those studies included 987 nonsmokers, including never-smokers and former smokers.
Sixteen were randomized trials, seven were crossover studies, and additional clinical study designs were also represented.
This provides a substantial human research history in which nicotine itself could be examined through a controlled transdermal preparation.
Researchers were able to ask what happened when people encountered nicotine under measured conditions.
Nicotine and Human Cognitive Performance
One of nicotine's most consistently interesting research areas is cognition.
A major meta-analysis examined 41 double-blind, placebo-controlled human laboratory studies.
Researchers found significant positive nicotine-related effects across six performance domains:
Fine motor performance
Alerting attention accuracy
Alerting attention response time
Orienting attention response time
Short-term episodic memory accuracy
Working-memory response time
The analysis included research designed to help distinguish direct cognitive effects from effects related simply to relief of nicotine withdrawal.
Together, these findings provide a substantial human foundation for continued investigation of nicotine and cognitive performance.
Attention May Be One of Nicotine's Most Interesting Effects
Attention sounds simple until we consider what the brain is actually doing.
At every moment, enormous amounts of sensory information compete for awareness.
The brain must decide:
What deserves attention?
What changed?
What should be remembered?
What requires action?
Nicotinic acetylcholine receptors participate in these processes.
That helps explain why attention repeatedly appears in human nicotine research.
Controlled nicotine studies have reported measurable effects involving alerting attention, orienting attention and response speed.
This points toward nicotine's interaction with the machinery the brain uses to select and process information.
Memory and Mental Processing
Attention and memory work together.
Information must first be noticed and processed before it can become useful memory.
Researchers have therefore explored nicotine in connection with:
Working memory
Episodic memory
Recognition
Information processing
Reaction time
Learning
Cognitive flexibility
Some of the most intriguing findings have come from older adults experiencing measurable changes in memory.
Mild Cognitive Impairment
A particularly important human study followed nonsmoking adults with amnestic mild cognitive impairment for six months.
Participants were randomly assigned to transdermal nicotine or placebo.
Researchers evaluated attention, memory, processing and broader cognitive performance.
The nicotine group demonstrated significant improvements in several measures involving attention, memory and psychomotor speed.
Six months is meaningful.
This was sustained controlled exposure rather than a single brief laboratory experiment.
It demonstrated that prolonged transdermal nicotine can produce measurable changes in human cognitive performance.
Mood and Late-Life Cognitive Health
Controlled transdermal nicotine has also entered human research involving mood and cognition together.
A 2024 study examined transdermal nicotine as an augmentation approach in 29 nonsmoking adults age 60 and older experiencing late-life depression while taking stable antidepressant therapy.
Over 12 weeks, researchers reported a 76% treatment-response rate and 59% remission rate.
Participants also showed improvement in executive function, particularly cognitive control, along with several self-reported affective measures.
This adds another intriguing human dimension to controlled nicotine research.
Mood, motivation, attention and cognitive processing involve overlapping neurological systems, including pathways influenced by nicotinic acetylcholine receptors.
The findings provide another reason to continue investigating nicotine's relationship with neurological and cognitive health.
Older Research Still Has Something to Teach Us
Therapeutic interest in nicotine and cognition did not begin recently.
Researchers have investigated nicotine, memory and neurological performance for decades.
That history deserves attention because older medical literature preserves observations that modern researchers can revisit with tools earlier investigators never had:
Advanced brain imaging
More precise receptor mapping
Genetic information
Improved cognitive testing
Better inflammatory biomarkers
Modern neurological imaging
Larger datasets
Scientific tools improve.
The observations recorded in older studies remain part of the research history.
Sometimes an old question becomes more valuable when a new generation finally has better ways to investigate it.
Ulcerative Colitis Gives Us Remarkable Human Evidence
One of the strongest examples of direct medicinal nicotine research involves ulcerative colitis.
In a landmark randomized, double-blind trial, researchers studied 72 people with active ulcerative colitis.
Participants received either transdermal nicotine or placebo for six weeks while continuing their existing therapy.
The results were striking.
Seventeen of 35 people receiving nicotine achieved complete symptomatic relief compared with 9 of 37 receiving placebo.
The nicotine group also experienced greater improvement in global clinical grade and histological grade, along with improvements in stool frequency, abdominal pain and urgency.
This is meaningful human clinical evidence.
People with an inflammatory intestinal disease received controlled transdermal nicotine, and researchers measured changes in symptoms and tissue-level disease assessment.
Ulcerative Colitis Research Continued
Researchers continued exploring this connection.
A later randomized, double-blind, placebo-controlled trial enrolled 64 nonsmoking people with mildly to moderately active ulcerative colitis and examined transdermal nicotine in relation to clinical disease activity.
Together, these studies established ulcerative colitis as one of the most important historical examples of nicotine being investigated medicinally.
And they opened another door.
Researchers began asking:
Why could nicotine influence inflammatory intestinal activity?
Nicotine, Immunity and Inflammation
The ulcerative-colitis research expanded interest in the relationship among:
nicotine → nicotinic receptors → immune cells → inflammatory signaling
Nicotinic receptors are part of communication networks extending far beyond the brain.
The immune system responds to chemical messages.
The nervous system produces chemical messages.
And the two systems communicate continuously.
This has led researchers toward the broader field of cholinergic immune regulation, including particular interest in the α7 nicotinic acetylcholine receptor.
Our companion page on Nicotine, Inflammation and Immune Signaling will explore this remarkable biology much more deeply.
For this page, the important finding is clear:
Controlled nicotine has produced measurable inflammatory and clinical responses in human research.
Long COVID Opened a New Nicotine Research Chapter
Long COVID brought nicotine patches into a very different area of human investigation.
Persistent post-infectious illness can involve combinations of:
Fatigue
Brain fog
Memory problems
Altered smell and taste
Exercise intolerance
Pain
Sleep disruption
Muscle weakness
Neurological symptoms
Autonomic symptoms
In 2023, German physician Marco Leitzke published a hypothesis and four clinical cases involving transdermal nicotine in people with post-COVID syndrome.
The observations introduced an intriguing research question involving nicotinic acetylcholine receptor signaling and persistent post-infectious symptoms.
Long COVID Research Expanded
A 2025 publication in Bioelectronic Medicine took the investigation considerably further.
Researchers examined low-dose transdermal nicotine in relation to Long COVID and ME/CFS symptoms and incorporated patient-reported outcomes alongside receptor imaging.
Across the survey population, 73.5% reported significant improvement in their symptoms following low-dose transdermal nicotine.
The publication also described PET imaging involving nicotinic acetylcholine receptors.
Following a ten-day course of transdermal nicotine in the reported patient, researchers observed a significant increase in available nicotinic receptor ligand-binding sites, alongside clinical improvement.
Together, the patient outcomes and receptor imaging provide an important human research signal linking transdermal nicotine, nicotinic receptor availability and post-infectious recovery.
It gives researchers something tangible to explore:
nicotine exposure + human improvement + measurable receptor-related change
Humans Often Show Us Where to Look Next
Long COVID provides a fascinating example of how discovery can develop.
People experience something.
Someone notices a pattern.
A clinician documents it.
Researchers develop a hypothesis.
Imaging or laboratory tools begin looking for measurable biological changes.
Larger human studies can then explore the pattern further.
Human experience and formal research can complement one another.
A person's experience can reveal what happened.
Research can begin investigating how it happened.
Both can contribute to discovery.
Cardiovascular Research With Controlled Nicotine
Nicotine patches have also been studied directly in people with cardiovascular disease.
This gives researchers valuable information because they can observe cardiovascular responses to measured nicotine delivered gradually through the skin.
Controlled human studies have examined transdermal nicotine in people with cardiovascular disease and coronary artery disease, including cardiac events, myocardial ischemia and heart rhythm.
These studies contribute valuable human information about controlled nicotine exposure in cardiac populations.
They also open interesting questions about delivery speed, receptor activity, inflammation and individual cardiovascular physiology.
An Emerging Heart-Inflammation Story
Nicotine research also reaches into experimental cardiovascular inflammation.
Researchers studying viral myocarditis have investigated nicotine's interaction with the α7 nicotinic acetylcholine receptor and the cholinergic anti-inflammatory pathway.
Experimental research has reported findings involving:
Reduced myocardial inflammation
Reduced inflammatory cytokines
Improved left-ventricular function
Improved survival in studied models
Changes in inflammatory immune signaling
This creates an intriguing biological connection between nicotine-responsive receptors and inflammatory processes occurring within heart tissue.
Dr. Bryan Ardis has helped bring public attention to nicotine and myocarditis research through his educational work on heart health.
The findings provide another reason to study nicotinic signaling beyond the nervous system.
Nicotine Delivery and Dependence
The question of dependence becomes more interesting when nicotine delivery is examined carefully.
Dependence is influenced by several factors:
Delivery speed
Amount
Frequency
Duration
Previous exposure
Reinforcement pattern
Individual neurobiology
A transdermal patch provides particularly gradual delivery.
The systematic review of transdermal nicotine research in nonsmokers reported no withdrawal symptoms or addictive behavior in the reviewed studies.
That observation deserves attention because hundreds of people without regular nicotine use were represented in the research.
It also illustrates why discussing nicotine without discussing delivery method can miss an important part of the story.
Gum and Patches Offer Different Possibilities
Gum and patches each provide distinct advantages depending upon the desired pattern of nicotine exposure.
Nicotine gum offers:
Measured oral nicotine
Shorter exposure
Flexible timing
Intermittent use
Greater control over when nicotine is introduced
Nicotine patches offer:
Measured transdermal nicotine
Gradual delivery
Sustained exposure
More stable nicotine availability
A useful research tool for prolonged receptor engagement
The larger lesson is simple:
Delivery changes the biological experience of nicotine.
Dr. Bryan Ardis and the Modern Nicotine Conversation
Dr. Bryan Ardis, D.C., deserves recognition in the modern conversation surrounding nicotine.
Through presentations, interviews and educational work, Dr. Ardis has encouraged audiences to look again at nicotine, nicotinic acetylcholine receptors and older medical literature and to consider whether the nicotine story contains possibilities deserving renewed attention.
His work has brought greater public attention to:
Nicotine gum
Nicotine patches
Nicotinic receptors
Neurological research
Cognition
Inflammation
Post-infectious illness
Heart-related nicotine research
Medicinal history of nicotine and tobacco
Older research deserving renewed examination
His contribution is especially valuable as a public educator drawing attention to research trails that many people may never otherwise encounter.
Researchers conduct studies.
Clinicians observe patients.
Patients contribute lived experience.
Educators help discoveries reach a wider audience.
Dr. Ardis has encouraged many people to return to a wonderfully simple question:
What does the nicotine research actually say?
That question is worth asking.
Nicotine Research Reaches Far Beyond One Condition
When the literature is viewed together, an interesting pattern appears.
Nicotine has been investigated across several areas of human health.
Brain function
Attention, memory, cognitive processing, mood and neurological function.
Digestive and inflammatory health
Ulcerative colitis, immune signaling and cholinergic inflammatory regulation.
Post-infectious illness
Long COVID, neurological symptoms and nicotinic receptor hypotheses.
Cardiovascular physiology
Controlled transdermal exposure in people with cardiovascular disease and experimental research involving inflammatory heart conditions.
Receptor biology
How nicotine interacts with nicotinic acetylcholine receptors throughout the human body.
These subjects begin to look much less disconnected once we recognize their common thread:
Nicotinic acetylcholine receptors are distributed throughout human biology.
Nicotine interacts with this network.
That is why nicotine research can travel from the brain to the intestine, immune system, heart and beyond.
Beginning Gently
Human transdermal research has used measured nicotine exposure, with investigators selecting amounts and schedules according to the population and biological question being studied.
This offers a valuable principle:
A biologically active compound can be respected through measured, thoughtful exposure.
Individual response varies.
Someone unfamiliar with nicotine may experience a particular amount differently from someone with previous exposure.
The goal is understanding the response rather than chasing intensity.
How Nicotine Gum Is Used
Nicotine gum is designed for oral absorption.
The commonly used technique is known as chew and park:
Chew slowly until the nicotine sensation becomes noticeable.
Rest the gum between the cheek and gum.
Allow absorption through the lining of the mouth.
Resume gentle chewing as the sensation fades.
Continue according to the particular product directions.
This technique allows nicotine to be absorbed gradually through oral tissues.
How Nicotine Patches Work
Nicotine patches deliver nicotine across the skin.
Commercial products are available in graduated strengths, allowing measured transdermal delivery.
A patch is generally placed on clean, dry skin according to the particular product's directions.
The slow-release design is what makes the patch especially interesting in research.
Instead of repeatedly introducing nicotine throughout the day, researchers can create a sustained period of receptor exposure.
How to Use It Wisely
Nicotine is biologically active, and individual response can vary according to amount, delivery method, previous exposure and personal sensitivity.
Human studies involving nicotine-naïve participants have used measured transdermal exposure, allowing researchers to observe responses over time.
Beginning gently respects the potency of nicotine while allowing individual response to guide the experience.
Gum and patch products are available in different strengths, making measured delivery possible. Product directions provide guidance for their labeled use, while research protocols investigating other applications may use different amounts and schedules.
When nicotine is being considered for a medical condition or another off-label purpose, individualized guidance from a knowledgeable healthcare professional can help connect the research with a person's particular circumstances.
What Controlled Nicotine Has Given Researchers
Nicotine gum and patches have created something extraordinarily useful.
Researchers can take a naturally occurring tobacco alkaloid and control:
Amount.
Delivery.
Duration.
Timing.
Then they can observe what happens in humans.
Attention can be measured.
Memory can be tested.
Mood can be followed.
Inflammatory disease can be observed.
Symptoms can be recorded.
Receptor availability can be imaged.
Cardiovascular responses can be studied.
Quality of life can be measured.
That is why gum and patches represent much more than two nicotine products.
They are research windows into nicotinic acetylcholine biology.
A Story That Is Still Unfolding
The nicotine research story spans generations.
Older physicians investigated inflammatory bowel disease.
Neuroscientists explored attention and memory.
Researchers studied older adults experiencing cognitive changes.
Investigators have explored mood and executive function.
Modern researchers are studying Long COVID and receptor availability.
Experimental researchers are examining inflammatory pathways reaching into the heart and immune system.
Patients continue contributing their experiences.
And people such as Dr. Bryan Ardis continue drawing public attention toward research that might otherwise remain buried in medical journals.
Different generations are asking different questions about the same remarkable molecule.
The answers continue revealing just how deeply nicotinic signaling is woven into human biology.
Nicotine gum and patches allow that story to be explored in measured, controlled and increasingly sophisticated ways.
There may still be much more to discover.
Questions and Answers
What is nicotine gum?
Nicotine gum is a measured oral preparation containing nicotine polacrilex. Nicotine is absorbed primarily through tissues in the mouth using the chew-and-park technique.
What is a nicotine patch?
A nicotine patch is a transdermal delivery system that releases nicotine gradually through the skin across many hours.
What is the biggest difference between nicotine gum and patches?
Nicotine gum provides shorter, adjustable exposure, while patches provide slower and more sustained exposure.
This gives each preparation different possibilities for controlled nicotine delivery.
Have nicotine patches been studied in people who did not regularly use nicotine?
Yes.
A systematic review identified 33 studies involving 987 nonsmokers receiving transdermal nicotine for longer than 48 hours.
Does nicotine affect attention?
Human research has found measurable positive effects involving several aspects of attention.
Controlled studies have reported effects involving alerting attention, orienting attention and other areas of cognitive performance.
Has nicotine been studied for memory?
Yes.
Researchers have explored nicotine in relation to working memory, episodic memory, age-associated memory changes and mild cognitive impairment.
Has nicotine been studied in people with mild cognitive impairment?
Yes.
A six-month randomized trial in nonsmoking adults with amnestic mild cognitive impairment found significant improvements in several cognitive measures involving attention, memory and mental processing.
Has transdermal nicotine been studied for mood?
Yes.
A 2024 study involving 29 nonsmoking older adults with late-life depression reported a 76% treatment-response rate and 59% remission rate during 12 weeks of transdermal nicotine augmentation.
Researchers also reported improvement in executive function, particularly cognitive control.
Has nicotine been studied for ulcerative colitis?
Yes.
Randomized human trials have investigated transdermal nicotine for active ulcerative colitis.
In a landmark trial, 17 of 35 people receiving nicotine achieved complete symptomatic relief compared with 9 of 37 receiving placebo, with additional improvements in clinical and histological measures.
Why would nicotine affect an inflammatory intestinal condition?
Nicotinic acetylcholine receptors participate in communication involving both the nervous and immune systems.
Research into nicotine and ulcerative colitis helped expand interest in cholinergic regulation of inflammatory signaling.
Is nicotine being researched for Long COVID?
Yes.
Published clinical observations and subsequent research have investigated transdermal nicotine, nicotinic acetylcholine receptors and persistent post-infectious symptoms.
A 2025 publication reported significant symptom improvement among 73.5% of surveyed participants following low-dose transdermal nicotine.
Has receptor imaging been used in nicotine and Long COVID research?
Yes.
The 2025 research included PET imaging and reported increased availability of nicotinic acetylcholine receptor ligand-binding sites following a ten-day course of transdermal nicotine in the studied patient, alongside clinical improvement.
Have nicotine patches been studied in people with cardiovascular disease?
Yes.
Controlled transdermal nicotine has been studied directly in people with cardiovascular disease, providing human information about gradual nicotine exposure in cardiac populations.
Is nicotine being researched in relation to heart inflammation?
Yes.
Experimental viral-myocarditis research has investigated nicotine and the α7 nicotinic acetylcholine receptor pathway, including effects involving inflammatory signaling and cardiac outcomes in studied models.
What has research found about dependence among nonsmokers using nicotine patches?
A systematic review of transdermal nicotine research involving nonsmokers reported no withdrawal symptoms or addictive behavior in the reviewed studies.
Why does nicotine delivery matter?
Delivery affects how quickly nicotine becomes available, how long exposure continues and how nicotinic receptors encounter it.
Gum and patches therefore create different biological exposure patterns.
Why is Dr. Bryan Ardis important to the nicotine conversation?
Dr. Bryan Ardis has helped bring nicotine gum and patches, nicotinic receptor biology, older nicotine research, neurological research, inflammation and emerging nicotine applications into wider public discussion.
His educational work has encouraged people to revisit research and explore questions that deserve continued investigation.
Is older nicotine research still valuable?
Yes.
Older clinical trials and human observations preserve important information. Modern imaging, biomarkers and receptor science give researchers additional tools for revisiting those discoveries.
Does nicotine need to create a strong physical sensation to be biologically active?
Nicotine can engage nicotinic receptor systems at biologically active exposures even when the physical sensation is subtle.
Why are researchers still interested in nicotine?
Nicotinic acetylcholine receptors participate in an extraordinary range of human functions involving cognition, neurological communication, movement, digestion, immune regulation and inflammation.
Controlled nicotine provides researchers with a way to investigate this system.
What is the larger lesson from nicotine gum and patch research?
Controlled delivery changes the story.
Once nicotine can be measured and delivered predictably, researchers can investigate the compound itself, observe human responses and study the remarkable receptor system with which nicotine interacts.
Decades of research have already produced meaningful human findings.
There is still much more to discover.